SCHEMBL6793324

SCHEMBL6793324

O=[N+]([O-])c1ccc(OCCc2ccccn2)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 1/20 0.54
KMT2A Q03164 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
MEN1 O00255 1/20 0.52
ALDH1A1 P00352 4/20 0.47
CYP19A1 P11511 6/20 0.46
CYP11B1 P15538 5/20 0.46
CYP11B2 P19099 5/20 0.46
APOBEC3A P31941 1/20 0.46
HTT P42858 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
POLB P06746 1/20 0.46
HSPB1 P04792 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 2/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6068967 0.87 S1PR4 (0.50) S1PR4KMT2ANPC1RAB9AMEN1
SCHEMBL6793846 0.79 KMT2A (0.62) KMT2ANPC1RAB9AMEN1ALDH1A1
SCHEMBL6500018 0.78 POLB (0.58) KMT2ANPC1RAB9AMEN1ALDH1A1
SCHEMBL6583238 0.78 S1PR4 (0.52) S1PR4KMT2ANPC1RAB9AALDH1A1
SCHEMBL6793640 0.77 ALDH1A1 (0.70) KMT2ANPC1RAB9AMEN1ALDH1A1
SCHEMBL3966375 0.76 NPC1 (0.66) KMT2ANPC1RAB9AMEN1ALDH1A1
SCHEMBL30963305 0.75 ALDH1A1 (0.44) KMT2ANPC1RAB9AMEN1ALDH1A1
SCHEMBL6794648 0.75 POLB (0.64) KMT2ANPC1RAB9AMEN1ALDH1A1
SCHEMBL4402735 0.74 S1PR4 (0.62) S1PR4KMT2ANPC1RAB9AALDH1A1
SCHEMBL3441990 0.74 S1PR4 (0.66) S1PR4KMT2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
CN-1478077-A Benzamide compounds as APO B secretion inhibitors ����ҩƷ��ҵ��ʽ���� 2004-02-25 CN disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 S1PR4 1093/4885KMT2A 2457/4885NPC1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.